Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2
Virchows Archiv, Volume 463, No. 5, Year 2013
Notification
URL copied to clipboard!
Description
Polycomb group (PcG) proteins are important for the regulation of hematopoiesis by regulating chromatin compaction and silencing genes related to differentiation and cell cycle. Overexpression of enhancer of zeste homologue 2 (Ezh2) and Bmi-1/PCGF4 has been implicated in solid organ cancers, while Mel-18/PCGF2 has been reported as a tumor suppressor. Detailed expression profiles of PcG proteins and their diagnostic significance in malignant lymphomas are still unknown. In this study, we analyzed the expression levels of Ezh2, Bmi-1, Mel-18, and Ki67 in 197 Hodgkin's and non-Hodgkin's lymphoma patient samples and in lymphoma cell lines using immunohistochemistry, fluorescent immunocytochemistry, and Western blotting. Immunohistochemical staining showed that Ezh2 expression was significantly increased in aggressive compared to indolent subtypes of B cell neoplasms (P = 0.000-0.030), while no significant differences in Bmi-1 expression were found between these subtypes. Compared to the normal counterpart, T cell lymphomas showed significant overexpression of Bmi-1 (P = 0.011) and Ezh2 (P = 0.000). The Ki67 labeling index showed a positive correlation with Ezh2 expression in B cell lymphomas (correlation coefficient (Co) = 0.983, P = 0.000) and T/NK cell lymphomas (Co = 0.629, P = 0.000). Fluorescent immunohistochemical staining showed coexpression of Ezh2 and Ki67 in the same tumor cells, indicating that Ezh2 expression correlates with cell proliferation. Both B and T/NK cell neoplasms showed low expression of Mel-18 and high expression of both Bmi-1 and Ezh2. In conclusion, in aggressive lymphoma variants, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. Coexpression of Bmi-1 and Ezh2 is a characteristic of aggressive lymphomas. Ezh2 correlates with the proliferation and aggressive nature of non-Hodgkin's lymphomas. © 2013 Springer-Verlag Berlin Heidelberg.
Authors & Co-Authors
Abd Al-Kader, Lamia
Japan, Okayama
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Egypt, Mansoura
Faculty of Medicine
Oka, Takashi
Japan, Okayama
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Takata, Katsuyoshi
Japan, Okayama
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sun, Xu
China, Dalian
Dalian Medical University
Sato, Hiaki
Japan, Okayama
Okayama University
Murakami, Ichiro
Japan, Okayama
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Japan, Yonago
Tottori University Faculty of Medicine
Toji, Tomohiro
Japan, Okayama
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Manabe, Akihiro
Japan, Okayama
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kimura, Hiroshi
Japan, Suita
Osaka University
Yoshino, Tadashi
Japan, Okayama
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Statistics
Citations: 37
Authors: 10
Affiliations: 6
Identifiers
Doi:
10.1007/s00428-013-1428-y
ISSN:
09456317
e-ISSN:
14322307
Research Areas
Cancer
Health System And Policy